Hamblin, Lavery Join Hologenix Board

Hologenix LLC, maker of Celliant technology, has completed its science advisory board with the appointments of Drs. Michael R. Hamblin and Lawrence A. Lavery. It also has established a research and development laboratory.

With more than 30 years of experience, Hamblin is the principal investigator at the Wellman Center for Photomedicine at Massachusetts General Hospital in Cambridge and an associate professor of dermatology at Harvard Medical School. He is also a member of the affiliated faculty of the Harvard-MIT Div. of Health Science and Technology.

Lavery is a professor of surgery at the University of Texas Southwestern Medical Center.

Hamblin and Lavery join Drs. Christopher Drake and Shimon Weiss. Dr. Michael Coyle, chief science officer for Hologenix, is chairman of the board.

The laboratory will collect data to generate original research for the peer-review process and publication. It will work closely with members of the board, along with additional collaborators, to maximize its contributions.

Celliant is patented technology that harnesses and recycles the body’s natural energy through the medium of fibers. Products containing this technology have been clinically proved to enhance tissue oxygen levels, improving athletic performance, sleep quality, health and wellness.

For more information, visit: www.celliant.com